LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Ekso Bionics Holdings, Inc. (“Ekso” or the “Company”) (NASDAQ: EKSO) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Ekso investigation page on our website at www.glancylaw.com.
On December 14, 2017, the Company disclosed material weaknesses in its internal control over financial reporting as of December 31, 2016, and that the Company’s representations regarding the effectiveness of its internal controls as of that date should no longer be relied upon. Then, on December 27, 2017 the Company filed amended quarterly and annual reports for the periods: FY 2016, Q1 2017, Q2 2017, and Q3 2017.
Over the course of these two disclosures, the Company’s share price declined, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Ekso securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.